Esperion puts hope in Rosenberg as new CMO
This article was originally published in Scrip
Esperion Therapeutics, the US company focused on cardiovascular and metabolic diseases, has appointed Dr Noah Rosenberg as its chief medical officer. He will lead the clinical advisory board and manage the company's clinical programmes, including managing the regulatory review process and corporate planning for financing development programmes. Previously, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi-Aventis and Forest Laboratories.
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.